title: Medical management of ectopic pregnancy: a 10-year case series.
abstract: OBJECTIVE
  The study was concerned with the medical management of ectopic pregnancy; specifically, (i) whether there is a significant increase in follow-up duration when the serum βhCG is greater than 3000 iu/l and (ii) an association between the serum βhCG concentration at presentation and the need for a repeat dose of Methotrexate and/or emergency surgical intervention, and if so, to try to quantify the probability of the requirement for either a repeat dose or surgery depending on serum βhCG concentration.
  
  
  METHODS
  A retrospective case note review of all medically treated ectopic pregnancies over a 10-year period in a tertiary referral hospital in the southwest of England.
  
  
  RESULTS
  398 women were identified in total. Three were excluded and five case notes could not be located. A βhCG ≤ 3000 iu/l occurred in 73.8%. Mean follow-up duration was 25.9 days when the βhCG was ≤ 3000 iu/l compared to 42.3 days when it was >3000 iu/l. When βhCG was ≤ 3000 iu/l, a repeat dose of Methotrexate and emergency surgery were required in 10.4 and 4.5% cases, respectively, compared to 21.6 and 14.7% when βhCG >3000 iu/l. All differences were statistically significant. By fitting logistic regression models to our data, a reference table indicating the risk of requiring a repeat dose of Methotrexate or subsequent surgery for any βhCG level has been created.
  
  
  CONCLUSIONS
  Although follow-up duration and the need for repeat doses of Methotrexate and/or surgical intervention increases with increasing serum βhCG, medical management is still safe and effective when the βhCG is >3000 iu/l and should be promoted.
authors.affiliation: Department of Obstetrics and Gynaecology, Derriford Hospital, Derriford Road, Crownhill, Plymouth, Devon PL6 8DH, UK. allyrichardson@hotmail.co.uk
authors.forename: Alison
authors.initials: A
authors.lastname: Richardson
mesh_terms: D018997:Chorionic Gonadotropin, beta Subunit, Human / Q000097:blood; D004739:England; D005260:Female; D059247:Fertility Preservation; D006801:Humans; D008727:Methotrexate / Q000008:administration & dosage; D011247:Pregnancy; D011271:Pregnancy, Ectopic / Q000097:blood / Q000188:drug therapy* / Q000601:surgery; D012189:Retrospective Studies; D012307:Risk Factors; D062606:Tertiary Care Centers; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D018997:Chorionic Gonadotropin, beta Subunit, Human; D008727:Methotrexate